Speedy EU, US review for Novartis’ CAR-T therapy Kymriah
Regulators on both sides of the Atlantic are undertaking speedy reviews of Novartis’ CAR-T therapy Kymriah.
Read More
Tag: ASCT
Revlimid boosts survival in myeloma patients post-transplant
Celgene has unveiled a meta-analysis of pooled data from three late-stage studies showing a significant overall survival benefit in patients newly diagnosed with multiple myeloma receiving Revlimid as maintenance therapy following autologous stem cell transplantation.
Read More
Final NICE nod for Takeda’s Adcetris in Hodgkin’s lymphoma
Certain patients with Hodgkin’s Lymphoma living in England and Wales can now expect routine access to Takeda’s Adcetris on the NHS after NICE deemed the drug a cost-effective use of resources in some scenarios.
Read More
EU expands use of Revlimid to include post ACST use
European regulators have expanded the scope of Celgene’s Revlimid to include its use as monotherapy for the maintenance treatment of adults with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation (ASCT).
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
